Overview

Gyre Therapeutics (“Gyre”) is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapeutics with its most advanced programs addressing organ fibrosis and inflammatory diseases.

In the United States, F351 (hydronidone) is currently being evaluated for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH)-associated liver fibrosis.

In the People’s Republic of China (PRC), Gyre Therapeutics, through its controlling interest in Gyre Pharmaceuticals, is advancing a broad pipeline of innovative drugs for organ fibrosis, including F351 for Chronic Hepatitis B (CHB)-associated liver fibrosis. Its flagship product, ETUARY™ (pirfenidone capsule), was the first approved treatment for Idiopathic Pulmonary Fibrosis (IPF) in the PRC.

Gyre’s wholly-owned subsidiary, Cullgen Inc., is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted protein degrader and degrader-antibody conjugate (DAC) therapies for critical conditions including cancer and inflammatory diseases. Cullgen has created a portfolio of highly selective targeted protein degrader and DAC product candidates designed to potently and efficiently eliminate therapeutically relevant proteins in patients.